SCCA2 as a biomarker reflecting patient‐reported disease burden in children with mild atopic dermatitis under maintenance therapy
Pediatric Allergy and Immunology · 2026
DOI: 10.1111/pai.70298 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Allergy and Immunology, 2026. Verfasst von Yasuaki Yasuda und 12 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Center NHO Mie National Hospital, Tsu, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Serpins, Antigens, Neoplasm. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Ministry of Health, Labour and Welfare.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
In mild atopic dermatitis (AD), evaluating disease activity during maintenance therapy is challenging due to subtle clinical signs. Serum squamous cell carcinoma antigen 2 (SCCA2) has been proposed as a sensitive biomarker, but its utility in assessing disease status specifically in mild AD remains unclear.
Objective
To assess the utility of serum SCCA2 in children with mild AD receiving maintenance therapy, focusing on its relationship with patient‐reported outcomes. Serum thymus and activation‐regulated chemokine (TARC), an established marker, was analyzed as a comparator.
Methods
Sixty‐nine pediatric patients with mild AD were enrolled. Clinical severity was assessed by the Eczema Area and Severity Index (EASI; physician‐rated) and the Patient‐Oriented Eczema Measure (POEM; patient‐reported). Baseline serum SCCA2 and TARC were measured. Associations were first examined using Spearman's rank correlation. Temporal associations between baseline SCCA2 and POEM at Days 3 and 7 were further evaluated using linear mixed‐effects models, and complementary bootstrap resampling and Steiger's Z test were applied for correlation comparisons.
Results
Although all patients were classified as mild by EASI, POEM scores ranged widely, indicating discordance between physician‐ and patient‐assessed severity. SCCA2, but not TARC, was significantly correlated with POEM scores at baseline. The correlation between baseline SCCA2 and POEM was strongest on Day 3 and attenuated by Day 7. Linear mixed‐effects modeling confirmed a significant time‐dependent association.
Conclusion
SCCA2 reflects patient‐experienced symptom burden more closely than physician‐assessed severity in mild AD. Its short‐term, time‐dependent association with POEM suggests potential utility for identifying early or imminent symptom burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Center NHO Mie National Hospital, Tsu, Japan.
- Department of Child Health and Development, Mie University Graduate School of Medicine, Tsu, Japan.
- Department of Pediatrics, NHO, Mie National Hospital, Tsu, Japan.
- Shino-Test Corporation, Sagamihara, Japan.
- Department of Pediatrics, Mie University Graduate School of Medicine, Tsu, Japan.
- Division of Allergy, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan.
ORCID-Profile: Takao Fujisawa
Förderung
- Ministry of Health, Labour and Welfare
Zitieren
APA
Yasuda, Y., Iwai, F., Hamada, K., Hoshi-Funakawa, M., Nogami, K., Matsunaga, M., Takase, T., Nagao, M., Suga, S., Azuma, Y., Hirayama, M., Izuhara, K., & Fujisawa, T. (2026). SCCA2 as a biomarker reflecting patient‐reported disease burden in children with mild atopic dermatitis under maintenance therapy. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.70298
Vancouver
Yasuda Y, Iwai F, Hamada K, Hoshi-Funakawa M, Nogami K, Matsunaga M, et al. SCCA2 as a biomarker reflecting patient‐reported disease burden in children with mild atopic dermatitis under maintenance therapy. Pediatric Allergy and Immunology. 2026. doi:10.1111/pai.70298
BibTeX
@article{Yasuda2026,
author = {Yasuda, Yasuaki and Iwai, Fumiko and Hamada, Kana and Hoshi-Funakawa, Miyuki and Nogami, Kazutaka and Matsunaga, Mayumi and Takase, Takafumi and Nagao, Mizuho and Suga, Shigeru and Azuma, Yoshinori and Hirayama, Masahiro and Izuhara, Kenji and Fujisawa, Takao},
title = {SCCA2 as a biomarker reflecting patient‐reported disease burden in children with mild atopic dermatitis under maintenance therapy},
journal = {Pediatric Allergy and Immunology},
year = {2026},
doi = {10.1111/pai.70298}
}
EUVIMED